Complex Rendelo Med Zrt.

Research at Complex Rendelo Med Zrt. focuses on conditions such as heart failure, atherosclerotic disease, and disorders of lipid metabolism, aiming to improve survival and reduce cardiovascular events.

• Evaluation of novel therapies for heart failure with reduced ejection fraction
• Combination studies of kidney‑protective agents and heart failure treatments
• Lipid‑lowering strategies targeting hyperlipidemia and familial hypercholesterolaemia
• Prevention of cardiovascular outcomes in patients with obesity and atherosclerotic disease

The site conducts 27 trials with 11 investigators, providing patients in Szekesfehervar access to cutting‑edge cardiovascular research.

The centre’s immune‑focused program investigates autoimmune conditions including primary Sjogren’s disease and systemic inflammatory disorders, seeking safer and more effective immunomodulation.

• JAK‑inhibitor studies for active psoriatic arthritis
• Safety assessment of new cytokine blockers in autoimmune disease
• Combination therapy trials for refractory immune‑mediated arthritis
• Long‑term tolerability of targeted agents in systemic autoimmune conditions

As a non‑commercial hospital, Complex Rendelo Med Zrt. offers participants the chance to contribute to therapies that could reshape immune disease management.

Studies in this therapeutic area address debilitating joint disorders such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with a focus on disease control and functional improvement.

• Head‑to‑head comparison of biosimilar and reference biologics in rheumatoid arthritis
• Evaluation of oral small‑molecule agents for active psoriatic arthritis
• Long‑term safety of disease‑modifying antirheumatic drugs (DMARDs)
• Patient‑reported outcome measures in axial spondyloarthritis treatment

With a portfolio of 27 clinical trials, the site enables patients to access innovative musculoskeletal therapies while supporting scientific advancement.

Research targeting skin‑related and connective‑tissue conditions explores agents that modulate inflammatory pathways, aiming to alleviate skin lesions and systemic manifestations.

• IL‑17 inhibition trials for psoriasis‑associated arthritis
• Assessment of skin symptom control with new biologics
• Targeted therapies for connective tissue involvement in systemic disease
• Quality‑of‑life outcomes in patients receiving novel skin‑focused treatments

Located in Szekesfehervar, Complex Rendelo Med Zrt. provides a collaborative environment where 11 investigators advance care for patients with skin and connective tissue disorders.